Abstract P2-12-03: A pilot study evaluating the benefits and feasibility of an exercise program for breast cancer patients receiving adjuvant chemotherapy.

2012 ◽  
Author(s):  
TM Petrella ◽  
S Laredo ◽  
P Oh ◽  
S Marzolini ◽  
E Warner ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Pilot Study ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Exercise Program ◽  
Breast Cancer Patients

scholarly journals The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study

BMC Cancer ◽  
2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Stefanie de Groot ◽  
Maaike PG Vreeswijk ◽  
Marij JP Welters ◽  
Gido Gravesteijn ◽  
Jan JWA Boei ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Pilot Study ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Short Term ◽  
Neo Adjuvant Chemotherapy

scholarly journals Additional Therapy with a Mistletoe Product during Adjuvant Chemotherapy of Breast Cancer Patients Improves Quality of Life: An Open Randomized Clinical Pilot Trial

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Wilfried Tröger ◽  
Zdravko Ždrale ◽  
Nevena Tišma ◽  
Miodrag Matijašević
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Pilot Study ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Pilot Trial ◽  
Control Group ◽  
Breast Cancer Patients ◽  
Open Label

Background. Breast cancer patients receiving adjuvant chemotherapy often experience a loss of quality of life. Moreover chemotherapy may induce neutropenia. Patients report a better quality of life when additionally treated with mistletoe products during chemotherapy.Methods. In this prospective randomized open-label pilot study 95 patients were randomized into three groups. All patients were treated with an adjuvant chemotherapy. The primary objective of the study was quality of life, the secondary objective was neutropenia. Here we report the comparison of HxA (n= 34) versus untreated control (n= 31).Results. In the explorative analysis ten of 15 scores of the EORTC QLQ-C30 showed a better quality of life in the HxA group compared to the control group (P<0.001toP=0.038in Dunnett-T3 test). The difference was clinically relevant (difference of at least 5 points, range 5.4–12.2) in eight of the ten scores. Neutropenia occurred in 7/34 HxA patients and in 8/31 control patients (P= 0.628).Conclusions. This pilot study showed an improvement of quality of life by treating breast cancer patients with HxA additionally to CAF. Although the open design may be a limitation, the findings show the feasibility of a confirmatory study using the methods described here.

Pilot Study of Bone Mineral Density in Breast Cancer Patients Treated with Adjuvant Chemotherapy

1998 ◽  
Vol 16 (1) ◽  
pp. 6-11 ◽  
Author(s):  
Judith A. Headley ◽  
Richard L. Theriault ◽  
Adrian D. Leblanc ◽  
Rena Vassilopoulou-Sellin ◽  
Gabriel N. Hortobagyi
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Pilot Study ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Bone Mineral ◽  
Breast Cancer Patients ◽  
Mineral Density

scholarly journals The role of adjuvant chemotherapy in stage I–III male breast cancer: a SEER-based analysis

2020 ◽  
Vol 12 ◽  
pp. 175883592095835
Author(s):  
Wei-Ping Li ◽  
Hong-Fei Gao ◽  
Fei Ji ◽  
Teng Zhu ◽  
Min-Yi Cheng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Male Breast Cancer ◽  
Tumour Size ◽  
Male Breast ◽  
Stage I ◽  
Breast Cancer Patients ◽  
Chemotherapy Group

Background and aims: Male breast cancer is an uncommon disease. The benefit of adjuvant chemotherapy in the treatment of male breast cancer patients has not been determined. The aim of this study was to explore the value of adjuvant chemotherapy in men with stage I–III breast cancer, and we hypothesized that some male patients may safely skip adjuvant chemotherapy. Methods: Male breast cancer patients between 2010 and 2015 from the Surveillance Epidemiology and End Results database were included. Univariate and multivariate Cox analyses were used to analyse the factors associated with survival. The propensity score matching method was adopted to balance baseline characteristics. Kaplan–Meier curves were used to evaluate the impacts of adjuvant chemotherapy on survival. The primary endpoint was survival. Results: We enrolled 514 patients for this study, including 257 patients treated with chemotherapy and 257 patients without. There was a significant difference in overall survival (OS) but not in breast cancer-specific survival (BCSS) between the two groups ( p < 0.001 for OS and p = 0.128 for BCSS, respectively). Compared with the non-chemotherapy group, the chemotherapy group had a higher 4-year OS rate (97.5% versus 95.2%, p < 0.001), while 4-year BCSS was similar (98% versus 98.8%, p = 0.128). The chemotherapy group had longer OS than the non-chemotherapy group among HR+, HER2–, tumour size >2 cm, lymph node-positive male breast cancer patients ( p < 0.05). Regardless of tumour size, there were no differences in OS or BCSS between the chemotherapy and non-chemotherapy cohorts for lymph node-negative patients (OS: p > 0.05, BCSS: p > 0.05). Adjuvant chemotherapy showed no significant effects on both OS and BCSS in patients with stage I (OS: p = 0.100, BCSS: p = 0.858) and stage IIA breast cancer (OS: p > 0.05, BCSS: p > 0.05). Conclusion: For stage I and stage IIA patients, adjuvant chemotherapy could not improve OS and BCSS. Therefore, adjuvant chemotherapy might be skipped for stage I and stage IIA male breast cancer patients.

Sign in / Sign up

Export Citation Format

Share Document